Welcome Message
Welcome to the 26th World Congress on Cancer and Diagnostics!
Date:April 26–27, 2027
Venue:Barcelona, Spain
Theme:Early Detection, Accurate Diagnosis, Better Outcomes in Cancer Care
It is our great pleasure to welcome researchers, oncologists, healthcare professionals, pathologists, diagnostic experts, academicians, and industry leaders from around the world to the 26th World Congress on Cancer and Diagnostics, taking place on April 26–27, 2027, in Barcelona, Spain.
Under the theme “Early Detection, Accurate Diagnosis, Better Outcomes in Cancer Care,”this congress aims to provide an international platform for sharing groundbreaking research, exploring innovative diagnostic technologies, and discussing the latest advancements in cancer prevention, detection, diagnosis, and treatment.
The congress will bring together distinguished experts and emerging researchers to exchange knowledge, present scientific discoveries, and explore new approaches to improving cancer care. Key discussions will focus on precision oncology, molecular diagnostics, cancer biomarkers, liquid biopsy, artificial intelligence in cancer diagnosis, personalized medicine, and advanced therapeutic strategies.
We believe that collaboration, innovation, and knowledge sharing are essential to advancing cancer research and improving patient outcomes. This gathering offers valuable opportunities to establish professional connections, encourage interdisciplinary collaboration, and inspire new ideas that can contribute to the future of oncology and diagnostic medicine.
We warmly invite you to join us in Barcelona for two days of scientific excellence, meaningful discussions, and global collaboration. Together, let us work toward a future where early detection, accurate diagnosis, and innovative treatments make a lasting difference in the lives of patients worldwide.
We look forward to welcoming you to Barcelona, Spain, on April 26–27, 2027!
About the Conference
The 26th World Congress on Cancer and Diagnostics, scheduled for April 26–27, 2027, in Barcelona, Spain, aims to bring together leading oncologists, cancer researchers, pathologists, radiologists, diagnostic specialists, healthcare professionals, academicians, and industry experts from across the globe. Centered on the theme “Early Detection, Accurate Diagnosis, Better Outcomes in Cancer Care,”the conference will focus on advancing cancer research, promoting innovative diagnostic approaches, and exploring effective strategies to improve cancer prevention, diagnosis, and treatment.
The conference will provide an international platform for sharing scientific knowledge, presenting recent research findings, and discussing emerging trends in oncology and diagnostic medicine. It will highlight important developments in early cancer detection, molecular diagnostics, cancer biomarkers, liquid biopsy, genomic profiling, precision oncology, artificial intelligence in cancer diagnosis, medical imaging, personalized medicine, and targeted therapies.
Through keynote lectures, plenary sessions, scientific presentations, poster sessions, and interactive discussions, participants will have opportunities to exchange ideas, explore clinical challenges, and learn about promising developments in cancer diagnostics and therapeutics. The event will also encourage collaboration among academic institutions, hospitals, research organizations, pharmaceutical companies, biotechnology firms, and diagnostic technology developers.
A key objective of the congress is to emphasize the importance of timely and accurate cancer diagnosis in improving treatment decisions and patient outcomes. By bringing together experts from different disciplines, the conference seeks to encourage the translation of scientific discoveries into practical clinical applications and support the development of more accessible, effective, and personalized cancer care.
The congress welcomes established researchers, clinicians, healthcare practitioners, research scholars, postgraduate students, and industry professionals who are passionate about advancing cancer science and diagnostic innovation. It will offer valuable opportunities for professional networking, knowledge exchange, research collaboration, and the development of new partnerships.
Barcelona, Spain, will provide an inspiring international setting for this scientific gathering. The conference aims to foster meaningful discussions, strengthen global collaboration, and contribute to ongoing efforts to improve cancer detection, diagnostic accuracy, and treatment outcomes worldwide.
Join us at the 26th World Congress on Cancer and Diagnostics 2027to share knowledge, discover emerging innovations, connect with experts, and contribute to a future where early detection and accurate diagnosis lead to better outcomes in cancer care.
Why Attend the 26th World Congress on Cancer and Diagnostics?
The 26th World Congress on Cancer and Diagnostics, taking place on April 26–27, 2027, in Barcelona, Spain, offers an international platform for researchers, oncologists, healthcare professionals, diagnostic specialists, academicians, and industry experts to explore the latest developments in cancer research and diagnostic medicine.
With the theme “Early Detection, Accurate Diagnosis, Better Outcomes in Cancer Care,”the congress aims to encourage scientific exchange, promote innovation, and strengthen collaboration among professionals committed to improving cancer care.
Key Reasons to Attend
-
Explore Scientific Innovations:Discover emerging advances in cancer research, early detection, molecular diagnostics, precision oncology, biomarkers, liquid biopsy, and personalized medicine.
-
Learn from Experts:Gain valuable insights from experienced researchers, clinicians, and specialists working in oncology and diagnostic technologies.
-
Share Your Research:Present your scientific findings, clinical studies, and innovative ideas through research presentations and poster sessions, subject to the conference program.
-
Expand Professional Networks:Connect with international researchers, healthcare practitioners, academic institutions, industry representatives, and potential collaborators.
-
Discover Advanced Technologies:Learn about developments in artificial intelligence, genomic profiling, advanced imaging, and other technologies transforming cancer diagnosis and treatment.
-
Encourage Research Collaboration:Exchange ideas, discuss current challenges, and explore opportunities for interdisciplinary and international research partnerships.
-
Enhance Professional Development:Broaden your scientific knowledge, gain exposure to emerging research trends, and strengthen your academic and professional profile.
-
Explore Career Opportunities:Interact with professionals from academia, clinical practice, biotechnology, pharmaceuticals, and diagnostic industries to build valuable professional connections.
-
Contribute to Better Cancer Care:Participate in discussions focused on improving diagnostic accuracy, supporting timely intervention, and advancing patient-centered cancer management.
Who Should Attend?
The congress welcomes oncologists, cancer researchers, pathologists, radiologists, laboratory professionals, healthcare practitioners, medical scientists, research scholars, postgraduate students, professors, pharmaceutical representatives, biotechnology experts, and diagnostic technology developers.
Join the 26th World Congress on Cancer and Diagnostics 2027in Barcelona, Spain, to exchange knowledge, discover new perspectives, build meaningful collaborations, and contribute to advancements in cancer research and diagnostic innovation.
Be part of the global scientific community working toward early detection, accurate diagnosis, and better outcomes in cancer care.
Target Audience
The 26th World Congress on Cancer and Diagnostics, scheduled for April 26–27, 2027, in Barcelona, Spain, welcomes a diverse global audience of professionals, researchers, academicians, and industry leaders dedicated to advancing cancer research, diagnostic innovation, and patient care.
The conference is designed for individuals and organizations interested in exploring the latest developments in oncology, early cancer detection, diagnostic technologies, and innovative treatment strategies.
Who Should Attend?
-
Oncologists and Clinical Oncologists
-
Cancer Researchers and Scientists
-
Pathologists and Histopathologists
-
Radiologists and Medical Imaging Specialists
-
Molecular Diagnostics Specialists
-
Clinical Laboratory Professionals
-
Medical and Healthcare Practitioners
-
Cancer Biologists and Tumor Researchers
-
Immunologists and Geneticists
-
Precision Medicine and Genomics Experts
-
Pharmaceutical and Biotechnology Professionals
-
Cancer Screening and Early Detection Specialists
-
Biomedical Engineers and Diagnostic Technology Developers
-
Artificial Intelligence and Medical Technology Researchers
-
Professors, Academicians, and University Faculty
-
Research Scholars, PhD Students, and Postgraduate Students
-
Clinical Trial Investigators and Research Coordinators
-
Healthcare Administrators and Hospital Representatives
-
Representatives of Research Institutes and Medical Organizations
-
Medical Device Manufacturers and Diagnostic Companies
-
Healthcare Innovators, Entrepreneurs, and Industry Leaders
Why This Audience Matters
Bringing together professionals from diverse disciplines encourages knowledge exchange, interdisciplinary collaboration, and the development of innovative approaches to cancer diagnosis and treatment. The congress aims to provide opportunities for participants to share research findings, discuss emerging technologies, build professional networks, and contribute to improving cancer care worldwide.
Join us in Barcelona, Spain, on April 26–27, 2027, to connect with the global cancer research and diagnostics community and help shape the future of oncology.
Sessions & Tracks
Session 01: Advances in Cancer Research and Oncology – This session focuses on the latest developments in cancer biology, tumor progression, molecular mechanisms, and translational research. It explores innovative approaches to cancer prevention, diagnosis, and treatment, including new therapeutic targets, tumor microenvironment research, and emerging clinical strategies. Researchers and healthcare professionals will have opportunities to share discoveries that contribute to scientific progress and improved cancer care.
Session 02: Early Cancer Detection and Screening – This session highlights the importance of identifying cancer at an early stage through effective screening programs and advanced diagnostic technologies. Topics include breast, cervical, colorectal, lung, and other cancer screening approaches, risk assessment, early diagnostic biomarkers, and emerging multi-cancer detection methods. Discussions will also address screening accuracy, timely referral, diagnostic follow-up, and strategies for improving access to early detection services.
Session 03: Cancer Diagnostics and Pathology – This session explores modern diagnostic methods used to identify, classify, and characterize different types of cancer. Key topics include histopathology, cytopathology, tissue biopsy, immunohistochemistry, tumor grading, and digital pathology. It will also examine diagnostic standardization, specimen quality, and the integration of pathological findings with molecular testing to support accurate diagnosis and appropriate treatment planning.
Session 04: Molecular Diagnostics and Cancer Biomarkers – This session focuses on molecular techniques used to detect cancer-associated genetic changes and clinically relevant biomarkers. Topics include DNA mutations, RNA expression, protein biomarkers, gene sequencing, PCR-based testing, and molecular tumor profiling. Participants will explore biomarker discovery, clinical validation, and the application of molecular diagnostics in cancer screening, prognosis, treatment selection, and disease monitoring.
Session 05: Liquid Biopsy and Circulating Tumor Biomarkers – This session examines minimally invasive diagnostic approaches that analyze tumor-associated material in blood and other biological fluids. Important topics include circulating tumor DNA, circulating tumor cells, cell-free DNA, extracellular vesicles, and liquid biopsy technologies. Discussions will cover applications in early detection research, molecular profiling, treatment monitoring, recurrence assessment, and the identification of emerging treatment resistance.
Session 06: Precision Oncology and Personalized Medicine – This session explores individualized cancer treatment based on tumor characteristics, molecular profiles, biomarkers, and patient-specific clinical information. Topics include genomic profiling, precision medicine, targeted treatment selection, pharmacogenomics, and molecular tumor classification. Participants will discuss how personalized approaches can support more informed clinical decisions, improve treatment selection, and address challenges related to accessibility, cost, and interpretation of complex molecular findings.
Session 07: Medical Imaging and Radiology in Cancer Diagnosis – This session highlights the role of advanced imaging technologies in cancer detection, staging, treatment planning, and follow-up. Topics include MRI, CT, PET, ultrasound, mammography, nuclear medicine, and image-guided biopsy. The session will also explore radiomics, AI-assisted image analysis, functional imaging, and innovations that may improve lesion characterization, diagnostic accuracy, and clinical decision-making.
Session 08: Artificial Intelligence and Digital Diagnostics in Oncology – This session focuses on the growing application of artificial intelligence, machine learning, and digital technologies in cancer diagnostics. Topics include AI-assisted radiology, digital pathology, automated tumor detection, predictive analytics, and computational analysis of molecular data. Discussions will address diagnostic performance, algorithm validation, data quality, privacy, bias, and the responsible integration of AI tools into clinical workflows.
Session 09: Cancer Immunology and Immunotherapy – This session examines the relationship between the immune system and cancer development, along with innovative treatments that use immune mechanisms to fight malignancies. Topics include immune checkpoint inhibitors, CAR-T cell therapy, cancer vaccines, tumor microenvironment, immune biomarkers, and mechanisms of treatment resistance. Participants will explore emerging research, therapeutic combinations, patient selection, and strategies for improving the safety and effectiveness of immunotherapy.
Session 10: Targeted Therapy and Novel Cancer Therapeutics – This session explores innovative treatments designed to target specific molecular pathways and biological characteristics of cancer cells. Topics include targeted drugs, monoclonal antibodies, antibody–drug conjugates, synthetic lethality, combination therapies, and mechanisms of drug resistance. Discussions will emphasize biomarker-guided treatment selection, therapeutic development, clinical trials, and the integration of diagnostic information into personalized cancer management.
Session 11: Breast Cancer Research and Diagnostics – This session focuses on advances in breast cancer prevention, screening, diagnosis, and treatment. Topics include mammography, breast ultrasound, MRI, biopsy techniques, molecular classification, hormone receptors, HER2 testing, and hereditary cancer risk assessment. Participants will discuss emerging biomarkers, artificial intelligence in breast imaging, targeted therapies, and strategies for improving early detection and individualized breast cancer care.
Session 12: Lung Cancer and Thoracic Oncology – This session examines developments in lung cancer screening, diagnostic evaluation, molecular characterization, and treatment. Topics include low-dose CT screening, pulmonary nodule assessment, bronchoscopy, tissue biopsy, genomic profiling, liquid biopsy, and molecular biomarkers. The session will also explore targeted therapies, immunotherapy, treatment resistance, and multidisciplinary approaches to improving diagnostic accuracy and outcomes in thoracic oncology.
Session 13: Gastrointestinal Cancer and Digestive Oncology – This session covers cancers of the esophagus, stomach, colon, rectum, liver, pancreas, and other digestive organs. Topics include colorectal cancer screening, endoscopy, histopathology, molecular diagnostics, genetic alterations, and biomarker-guided treatment. Participants will explore advances in early detection, diagnostic imaging, precision oncology, treatment monitoring, and multidisciplinary management of gastrointestinal malignancies.
Session 14: Hematologic Malignancies and Blood Cancer Diagnostics – This session focuses on the diagnosis and management of leukemia, lymphoma, multiple myeloma, and other blood cancers. Topics include blood film examination, bone marrow analysis, flow cytometry, cytogenetics, molecular testing, and next-generation sequencing. Discussions will also cover measurable residual disease, molecular monitoring, targeted treatments, immunotherapy, and diagnostic innovations that support accurate classification and treatment decisions.
Session 15: Pediatric Oncology and Childhood Cancers – This session explores advances in the diagnosis, treatment, and long-term management of cancers affecting children and adolescents. Topics include childhood leukemia, lymphoma, brain tumors, neuroblastoma, sarcomas, genetic predisposition, and molecular tumor profiling. Participants will discuss innovative therapies, early recognition, treatment-related complications, survivorship, psychosocial support, and approaches to improving access to specialized pediatric cancer care.
Session 16: Cancer Genomics, Epigenetics and Gene Regulation – This session examines the genetic and epigenetic mechanisms that contribute to cancer development, progression, and treatment resistance. Topics include oncogenes, tumor suppressor genes, DNA methylation, histone modifications, non-coding RNA, chromosomal alterations, and gene-expression profiling. The session will also explore next-generation sequencing, single-cell analysis, multi-omics research, and the application of genomic discoveries to cancer diagnostics and personalized medicine.
Session 17: Clinical Trials and Translational Cancer Research – This session focuses on translating laboratory discoveries into clinical applications that can benefit patients. Topics include clinical trial design, biomarker validation, investigational therapies, translational oncology, patient recruitment, and research methodology. Participants will discuss clinical evidence, ethical considerations, regulatory requirements, and the role of clinical trials in evaluating new diagnostic technologies and therapeutic approaches.
Session 18: Radiation Oncology and Multidisciplinary Cancer Care – This session highlights advances in radiation-based cancer treatment and the importance of collaboration among healthcare specialists. Topics include intensity-modulated radiotherapy, image-guided radiotherapy, stereotactic techniques, brachytherapy, treatment planning, and radiobiology. Discussions will also cover treatment safety, toxicity management, combined treatment strategies, and multidisciplinary decision-making to support effective and individualized cancer care.
Session 19: Cancer Prevention, Survivorship and Palliative Care – This session explores comprehensive approaches to reducing cancer risk, supporting recovery, and improving quality of life throughout the cancer journey. Topics include lifestyle interventions, vaccination, hereditary risk assessment, survivorship care, rehabilitation, symptom management, and palliative medicine. Participants will discuss patient-centered care, psychological support, long-term monitoring, prevention strategies, and equitable access to supportive services for patients and families.
Session 20: Emerging Technologies and the Future of Cancer Diagnostics – This session explores innovative technologies that may transform the future of cancer detection, diagnosis, and monitoring. Topics include next-generation sequencing, multi-omics, advanced biosensors, microfluidic devices, digital health, point-of-care diagnostics, and emerging molecular testing platforms. Discussions will address technology validation, clinical implementation, affordability, accessibility, and the responsible development of diagnostic innovations to support earlier detection and better outcomes in cancer care
Market Analysis Report
The global cancer diagnostics market is expected to experience significant growth in the coming years, driven by the increasing prevalence of cancer, rising demand for early detection, technological advancements, and the growing adoption of precision medicine. According to market research estimates, the global cancer diagnostics market was valued at approximately USD 126.4 billion in 2026 and is projected to reach USD 191.1 billion by 2033. This represents substantial expansion in the demand for advanced diagnostic technologies, laboratory testing, imaging solutions, and personalized cancer care. Key growth opportunities include molecular diagnostics, liquid biopsy, next-generation sequencing (NGS), AI-assisted cancer detection, digital pathology, and biomarker testing. These technologies are becoming increasingly important for improving diagnostic accuracy, identifying cancer at earlier stages, monitoring treatment responses, and supporting individualized treatment decisions.
The liquid biopsy market is another promising segment within the broader cancer diagnostics industry. Its value is estimated to increase from approximately USD 16.2 billion in 2026 to USD 32.6 billion by 2033, reflecting strong demand for minimally invasive testing methods. Liquid biopsy technologies analyze cancer-associated biomarkers, including circulating tumor DNA, in blood and other bodily fluids. These methods may help clinicians monitor disease progression, identify certain molecular changes, and assess treatment responses without relying exclusively on invasive tissue biopsies. Although their clinical applications continue to expand, their suitability depends on the cancer type, clinical setting, and performance of the individual test. Similarly, the next-generation cancer diagnostics market is projected to grow from approximately USD 19.7 billion in 2026 to USD 41.1 billion by 2033. This growth is supported by increasing demand for genomic profiling, molecular characterization of tumors, companion diagnostics, and targeted treatment selection.
Another major factor contributing to market expansion is the increasing need for reliable diagnostic solutions throughout the cancer care pathway, from screening and initial diagnosis to treatment selection and post-treatment monitoring. Healthcare providers are increasingly adopting molecular profiling and biomarker testing to identify tumor characteristics and guide therapeutic decisions. Advances in medical imaging, immunohistochemistry, automated laboratory systems, and digital pathology are also helping improve diagnostic workflows. Artificial intelligence is emerging as a valuable tool for analyzing medical images, supporting pathology assessments, identifying patterns in complex datasets, and improving laboratory efficiency. As these technologies mature, their successful integration into clinical practice will depend on diagnostic accuracy, clinical validation, regulatory approval, affordability, and compatibility with existing healthcare systems.
Regionally, North America remains an important market for cancer diagnostics because of its established healthcare infrastructure, substantial investment in research and development, and the presence of leading biotechnology and diagnostic companies. Europe also represents a significant market, supported by advanced medical facilities, oncology research networks, precision medicine initiatives, and collaboration between academic institutions and industry. Meanwhile, the Asia-Pacific region offers considerable growth potential as healthcare infrastructure expands, public awareness increases, and access to cancer screening and diagnostic services improves in countries such as China, India, and Japan. These regional developments are creating opportunities for international research collaborations, technology transfer, clinical trials, and the development of more accessible diagnostic solutions. Nevertheless, differences in healthcare spending, reimbursement policies, regulatory frameworks, and access to specialized laboratories may influence the pace of market growth across individual countries.
Looking ahead to 2030–2035, the cancer diagnostics industry is expected to be shaped by continued innovation in genomic testing, liquid biopsy, AI-assisted diagnostics, digital pathology, multi-cancer early-detection research, and personalized oncology. Increasing emphasis on preventive healthcare and early diagnosis is also expected to encourage investment in screening programs and advanced testing technologies. However, challenges such as the high cost of diagnostic equipment, unequal access to healthcare, shortages of trained professionals, data privacy concerns, and the need for standardized testing procedures may affect widespread adoption. Emerging diagnostic technologies will also need to demonstrate meaningful clinical benefits, reliability, and cost-effectiveness before they can become routine components of cancer care.
